MYOS to Initiate a New Clinical Study on MYO-T12; Company Plans to Introduce Muscle Health Products for Women

CEDAR KNOLLS, NJ--(Marketwired - Jun 19, 2013) - MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of products that improve human muscle health and performance, today announced that it has completed the protocol design for a new clinical study on the effects of MYO-T12 in females. MYO-T12 is the Company's flagship product and the first clinically demonstrated natural myostatin inhibitor.

MYOS will conduct this study at a national contract research organization (CRO) in healthy women between the ages of 18 to 45, evaluating the use of MYO-T12 as dietary supplement for reducing serum myostatin levels. It expects the study will begin early in the third quarter and will be completed around year end.

Previous clinical studies have demonstrated that MYO-T12 suppresses serum myostatin levels in men. Myostatin suppression has been shown to enhance muscle growth, recovery and healing. The new clinical study involving healthy women is designed to show that MYO-T12 is well tolerated in women, effective at suppressing myostatin and may offer benefits which include improvement in muscle recovery and building and retaining healthy, lean muscle mass. Increased lean muscle mass should result in higher metabolism in women and allow for healthy weight management.

MYOS President and Chief Operating Officer, Peter Levy, commented on this important development: "We have been encouraged by the strong, early performance of MYO-T12 currently sold in the male sports nutrition market under the brand MYO-X. It is clear that female athletes and fitness enthusiasts are seeking novel and innovative dietary supplement and nutritional products capable of improving their muscle health and performance. The study we are initiating is the first step in broadening the total addressable market for our lead product.

"Just in the U.S. alone, our female target market will include many millions of women active in fitness, recreation and sports activities as well as those women facing age-related loss of muscle tissue known as sarcopenia," Mr. Levy added. "We see a large and growing market emerging as medical science continues to establish the critical role of muscle tissue health in overall wellness, and as a cornerstone to the prevention and treatment of chronic or age related disease."

Dr. Louis Aronne, member of both the MYOS Board of Directors and Scientific Advisory Boards, commented, "In line with our commitment to muscle health, the new clinical study should enable MYOS to demonstrate that MYO-T12 offers women a safe, natural dietary supplement that will allow them to improve their muscle mass and maintenance, and potentially help them with healthy weight management -- all critical factors in overall wellness."

About MYOS Corporation
MYOS is a developmental stage company focused on the discovery, development and commercialization of products that improve human muscle health and performance. MYOS is the owner of MYO-T12, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.

The Company's first commercial product MYO-X, powered by MYO-T12, is distributed by Maximum Human Performance (MHP) and is currently available on popular e-tailer websites including www.mhpstrong.com, www.bodybuilding.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that MYO-X, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of MYO-T12 and its effects on myostatin inhibition, including the clinical study described herein, product and customer demand, the continued growth of repeat purchases, market acceptance of our products, the ability to create new products through research and development, the continued growth in revenue, the ability to generate the forecasted revenue stream and cash flow from sales of MYO-X, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.